rubidium(1+);carbonate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: rubidium(1+);carbonate
• 化学式: CO3Rb2
• 分子量: 230.944
• InChiKey: WPFGFHJALYCVMO-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -8.44
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.2
• 氢给体数：
  0
• 氢受体数：
  3

ADMET

毒理性

• 副作用

神经毒素 - 其他中枢神经系统神经毒素

Neurotoxin - Other CNS neurotoxin

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

反应信息

• 作为反应物：
  描述：

  rubidium(1+);carbonate 、 硼酸 生成 oxido(oxo)borane;rubidium(1+)
  参考文献：
  名称：

  ASANO, M.;KOU, T., PHYS. AND CHEM. GLASSES , 30,(1989) N, C. 39-45

  摘要：

  DOI：
• 作为产物：
  描述：

  五羰基铁 、 rubidium hydroxide 生成 rubidium(1+);carbonate
  参考文献：
  名称：

  MITSUDO, TAKE-AKI;KOMIYA, YUKIATSU;BOKU, HIDEKI;ISHIHARA, ATSUSHI;MURACHI+, J. JAP. PETROL. INST., 31,(1988) N 1, 62-70

  摘要：

  DOI：

文献信息

• Nitrogen-heterocyclic compound and process for production thereof
  申请人：Tosoh Corporation

  公开号：US06346621B1

  公开（公告）日：2002-02-12

  A nitrogen-heterocyclic compound is provided which is represented by General Formula (1): where R1 and R2 are independently hydrogen, an alkyl group, an aryl group, or a heteroaryl group; R3 is hydrogen or an aryl group; R4 is a substituted amino group, an alkoxy group, a nitro group, or halogen; m is an integer from 0 to 2; and n is 0 or 1. A process for producing the above compound is also provided. This compound is useful as a source material of medicines, pesticides, electronic materials, and intermediates for other substituted nitrogen-heterocyclic compounds.

  本发明提供了一种由通式（1）表示的含氮杂环化合物，其中R1和R2分别独立表示氢、烷基、芳基或杂芳基；R3表示氢或芳基；R4表示取代氨基、烷氧基、硝基或卤素；m为0至2的整数；n为0或1。还提供了制备上述化合物的方法。该化合物可用作药物、杀虫剂、电子材料的原材料以及其他取代含氮杂环化合物的中间体。
• PRODRUG OF TRIAZOLONE COMPOUND
  申请人：Clark Richard

  公开号：US20130053563A1

  公开（公告）日：2013-02-28

  By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation.

  通过口服下述式（I）所表示的化合物：血液中的化合物（IV）：具有对血凝因子VIIa的优异抑制作用和抗凝作用，达到足以表现其药理作用的水平。因此，本发明的化合物可用作治疗和/或预防由血栓形成引起的疾病的药物。
• Prodrug of triazolone compound
  申请人：Clark Richard

  公开号：US08436009B2

  公开（公告）日：2013-05-07

  By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation.

  通过口服给予以下化学式（I）所代表的化合物，可以使具有出色抑制血液凝固因子VIIa和抗凝作用的化合物（IV）的血液水平达到足以表现其药理作用的水平。因此，本发明的化合物可用作治疗和/或预防由血栓形成引起的疾病的药物。
• Methods To Recover Cesium Formate From A Mixed Alkali Metal Formate Blend
  申请人：Cabot Corporation

  公开号：US20150152033A1

  公开（公告）日：2015-06-04

  Methods to recover or separate cesium formate or rubidium formate or both from a mixed alkali metal formate blend are described. One method involves adding cesium sulfate or rubidium sulfate to the mixed alkali metal formate blend in order to preferentially precipitate potassium sulfate from the mixed alkali metal formate blend. Another method involves adding cesium carbonate or cesium bicarbonate or both to preferentially precipitate potassium carbonate/bicarbonate and/or other non-cesium or non-rubidium metals from the mixed alkali metal blend. Further optional steps are also described. Still one other method involves converting cesium sulfate to cesium hydroxide.

  本文描述了从混合碱金属甲酸盐混合物中回收或分离氟化铯或氟化铷或两者的方法。其中一种方法涉及向混合碱金属甲酸盐混合物中添加硫酸铯或硫酸铷，以优先沉淀出混合碱金属甲酸盐混合物中的硫酸钾。另一种方法涉及向混合碱金属甲酸盐混合物中添加碳酸铯或碳酸氢铯或两者，以优先沉淀出碳酸盐/碳酸氢盐钾和/或其他非铯或非铷金属。还描述了其他可选步骤。还有一种方法涉及将硫酸铯转化为氢氧化铯。
• ASANO, M.;KOU, T., PHYS. AND CHEM. GLASSES , 30,(1989) N, C. 39-45
  作者：ASANO, M.、KOU, T.

  DOI：——

  日期：——

表征谱图